Nunzia Pharmaceutical Company
NUNZ
$0.00
$0.000.00%
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 227.40K | 20.10K | 18.72M | 78.00M | 34.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 227.40K | 20.10K | 18.72M | 78.00M | 34.50K |
| Operating Income | -227.40K | -20.10K | -18.72M | -78.00M | -34.50K |
| Income Before Tax | -236.40K | -20.10K | -18.72M | -78.01M | -34.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -236.40K | -20.10K | -18.72M | -78.01M | -34.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -236.40K | -20.10K | -18.72M | -78.01M | -34.50K |
| EBIT | -227.40K | -20.10K | -18.72M | -78.00M | -34.50K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | -0.04 | -0.22 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.03 | -0.14 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | -0.04 | -0.22 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.03 | -0.14 | 0.00 |
| Average Basic Shares Outstanding | 434.44M | 434.19M | 434.12M | 348.82M | 292.77M |
| Average Diluted Shares Outstanding | 434.44M | 434.19M | 434.12M | 348.82M | 292.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |